Floatz logo

Inno-206

Clear Cell Carcinoma

Yonsei UniversityPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Clear Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Dana-Farber Cancer Institute
Phase 2B
Rucaparib
North Eastern German Society of Gynaecological Oncology
Phase 3B
Lorigerlimab
MacroGenics
Phase 2CCC
Dostarlimab
Yonsei University
Phase 2CCC
NKT2152
NiKang Therapeutics, Inc.
Phase 1/2CCC

View all 20 →

Same molecule, other indications

Inno-206 is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
Recurrent Adult Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →